Form 4: Karyopharm Exec Sells Shares for Tax Obligation

Karyopharm Therapeutics' EVP, Chief Development Officer Stuart Poulton, sold 378 shares of common stock to cover tax liabilities from restricted stock unit vesting.

Summary

• Stuart Poulton, EVP, Chief Development Officer of Karyopharm Therapeutics Inc. (KPTI), sold 378 shares of the company's common stock.
• The transaction occurred on February 17, 2026, at a price of $8.63 per share.
• This sale was executed under a durable automatic sale instruction plan (Rule 10b5-1 plan) adopted by Mr. Poulton on May 18, 2022.
• The purpose of the sale was to satisfy withholding tax liability incurred upon the vesting of restricted stock units.
• The sale was a broker-assisted transaction and does not represent a discretionary trade by Mr. Poulton.
• Following this transaction, Mr. Poulton directly beneficially owns 99,429 shares of Karyopharm Therapeutics common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sale is non-discretionary and for tax purposes, indicating no change in management's underlying sentiment towards the company.

Future Outlook

No specific future outlook or guidance is provided in this filing, as it pertains solely to an insider transaction.

Management Comments

• This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 18, 2022, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units.
• The sale does not represent a discretionary trade by the reporting person.

Industry Context

StockSavvy.ai notes that routine insider sales for tax purposes, especially those executed under Rule 10b5-1 plans, are common across the biotechnology and pharmaceutical sectors. These transactions are typically not indicative of management's sentiment regarding the company's future prospects, unlike discretionary sales.

Comparison to Industry Standards

• This type of non-discretionary sale for tax withholding is a standard practice for executives receiving equity compensation across all industries, including biotech companies like Amgen, Gilead Sciences, and Biogen.
• It aligns with typical compensation structures and tax obligations for restricted stock unit vesting, where a portion of vested shares is sold to cover statutory tax liabilities.

Stakeholder Impact

• Minimal impact on shareholders as this is a routine, non-discretionary transaction for tax purposes and does not signal a change in management's confidence.
• No direct impact on employees, customers, suppliers, or creditors.

Key Dates

Recommendation

The transaction is a routine, non-discretionary sale by an executive to cover tax obligations arising from restricted stock unit vesting, executed under a pre-arranged Rule 10b5-1 plan. This type of insider activity typically does not reflect a change in the executive's confidence in the company's future prospects and therefore does not warrant a change in investment recommendation based solely on this filing. Investors should continue to hold and evaluate Karyopharm Therapeutics based on its operational performance and strategic developments.

Keywords

Karyopharm Therapeutics, KPTI, Stuart Poulton, Insider Trading, Form 4, Stock Sale, Tax Withholding, Restricted Stock Units, Rule 10b5-1